Showing 4881-4890 of 20470 results for "".
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://reachmd.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- Lebrikizumab Shows Durable Efficacy Through 4 Years in Atopic Dermatitishttps://reachmd.com/news/lebrikizumab-shows-durable-efficacy-through-4-years-in-atopic-dermatitis/2486468/Long-term data from the Phase 3b ADlong study show that lebrikizumab provides sustained skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis (AD), according to findings presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- New Clinical Trial Results Reported for Pulmonary Embolism and Atrial Fibrillation Deviceshttps://reachmd.com/news/new-clinical-trial-results-reported-for-pulmonary-embolism-and-atrial-fibrillation-devices/2486460/Boston Scientific has presented new clinical data that may reshape interventional approaches to both pulmonary embolism (PE) and stroke prevention in atrial fibrillation (AF), according to findings highlighted during a recent
- SkinPen Milestone Highlights Growth in Microneedling Demandhttps://reachmd.com/news/skinpen-milestone-highlights-growth-in-microneedling-demand/2486459/Revance announced that it has distributed more than 1 million SkinPen treatment kits nationwide since January 2025, marking a milestone for the company’s microneedling portfolio. The achievement comes approximately 1 year after the launch of SkinPen Precision Elite, the latest iteration of the de
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://reachmd.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Study Supports Safety, Efficacy of Subcutaneous Forehead Lift for Upper Facial Aginghttps://reachmd.com/news/study-supports-safety-efficacy-of-subcutaneous-forehead-lift-for-upper-facial-aging/2486458/A retrospective analysis published in Frontiers in Surgery evaluated the effectiveness and safety of subcutaneous forehead lift (SFL) for reducing horizontal forehead and glabellar wrinkles using the validated Wrinkle Assessment Scale (WAS). The study included 697 patients treated at a s
- Zasocitinib Demonstrates Biologic-Level Efficacy in Psoriasishttps://reachmd.com/news/zasocitinib-demonstrates-biologic-level-efficacy-in-psoriasis/2486453/Zasocitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated rapid and robust efficacy with a consistent safety profile in moderate-to-severe plaque psoriasis, according to Phase 3 LATITUDE-PsO-3001 and LATITUDE-PsO-3002 trial results presented by Melinda Gooderham, MD, MSc, at
- Envudeucitinib Outperforms Placebo and Apremilast in Phase 3 Psoriasis Trialshttps://reachmd.com/news/envudeucitinib-outperforms-placebo-and-apremilast-in-phase-3-psoriasis-trials/2486447/Envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated significant efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to Phase 3 data from the ONWARD 1 and ONWARD 2 trials presented by Andrew Blauvelt, MD, MBA,
- Epigenetic Markers May Predict Progesterone Resistance in Endometriosishttps://reachmd.com/news/epigenetic-markers-progesterone-resistance-endometriosis/2486437/Investigators at Yale School of Medicine reported that blood-based DNA methylation patterns might help distinguish subgroups of
- AAD 2026: Allergan Aesthetics Highlights TrenibotE Data and GLP-1 RA Patient Trendshttps://reachmd.com/news/aad-2026-allergan-aesthetics-highlights-trenibote-data-and-glp-1-patient-trends/2486432/Allergan Aesthetics, an AbbVie company, presented four posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, including new findings on repeat treatment with investigational trenibotulinumtoxinE (TrenibotE) and insights into aesthetic trends among patients r